<ul>
<li>Zymeworks 为不仅仅是长期投资者带来了希望</li>
</ul>
<p>Zymeworks（纳斯达克代码：ZYME）在 Bloom Burton 会议上使用了一次演示，概述了公司如何围绕其首个获批产品和不断增长的特许权使用费及里程碑收入进行重新定位，同时继续在抗体药物偶联物（ADCs）和多特异性抗体方面投资内部研发。</p>
<p>发言者指出，这是他们五年来首次在投资者会议上展示 Zymeworks 的股票 “高于五年前的水平”，并将此次更新与他们所描述的生物技术领域情绪改善相结合，包括并购活动的增加和投资者对该领域创新的重新认可。</p>
<h2>特许权使用费改变公司的财务战略</h2>
<p>演讲者表示，Zymeworks 现在拥有 “我们的首个获批药物”，提供了支持新运营模式的收入来源。尽管公司没有自己的商业组织，发言者将合作伙伴主导的销售收入描述为 “持久、长期且非常可观”，使 Zymeworks 能够考虑作为 “自筹资金实体” 运营，而不是依赖股权发行来资助开发。</p>
<p>他们补充说，公司最近与 Royalty Pharma 完成了一项融资，将其描述为借用未来现金流以投资于 “研发、收购和向股东返还资本”。演讲者表示，公司 “资金充足”，引用了 2.71 亿美元（并指出该数字不包括 2.5 亿美元的特许权使用费收入），并认为讨论已从现金周转转向资本配置。</p>
<p>“我们没有资本问题，我们有资本配置问题，” 发言者表示，描述了通过平衡内部创新与有纪律的支出以及新的现金流部署方式来建立股东价值的目标。</p>
<h2>Zanidatamab 作为新模型的基础</h2>
<p>战略转变以 zanidatamab 为中心，市场名称为 Ziihera，演讲者表示该药物是在 Zymeworks 发明并推进至第三阶段，然后与 Jazz Pharmaceuticals 和 BeOne（前身为 BeiGene）合作。发言者强调，合作伙伴结构保留了他们所称的未来特许权使用费和里程碑的 “相当可观份额”。</p>
<p>回顾过去，演讲者表示 Zymeworks 在 2022 年将 zanidatamab 视为潜在的 “十亿美元化合物”，但认为预期已经上升。他们表示，现在 “超出共识”，并补充道：“我们认为 zanidatamab 将成为一个数十亿美元的畅销药。” 他们将这一观点归因于临床数据和在其他适应症中的潜在适用性，并强调他们所看到的 HER2 领域的差异化，表示 “Zani 是唯一一个” 在市场上或正在开发的 HER2 双特异性抗体。</p>
<p>发言者还表示，预期的特许权使用费流的持久性支持了长期规划，描述现金流将持续 “至少到 2039 年，甚至更久。” 在此基础上，他们表示 Zymeworks 的目标是作为一家 “正收入公司” 运营，保持 “长期增长的收入”，并将其转化为盈利，同时仍然投资于研发。</p>
<h2>管道重点和 AACR 更新</h2>
<p>在研发方面，演讲者表示 Zymeworks 保持着 “非常充实的管道”，包括 ADCs 和多特异性抗体。他们指出，除了 zanidatamab 外，公司管道资产是 “未合作的”，这为未来的合作提供了 “很多选择”，同时保持潜在的上行空间不受限制。</p>
<p>在美国癌症研究协会（AACR）会议上，发言者表示 Zymeworks 有七个演示，主要集中在其 ADC 平台上。他们强调了当天安排的 ZW191 的口头报告，该 ADC 针对卵巢癌肿瘤，并表示将会有新闻稿伴随数据发布。</p>
<p>他们还花时间讨论了他们所描述的下一代 ADC 概念，包括旨在传递全 RAS 抑制剂的载荷。演讲者表示，公司探索了多种载荷方向——例如不同的毒素、双特异性抗体和蛋白降解剂——然后选择测试小分子抑制剂在通过 ADC 构建传递时是否更有效。</p>
<p>他们将这种方法描述为早期阶段，但表示目标是追求具有改善耐受性的活性，以便能够实现联合方案。“我们认为 ADC 构建可以提供相同或更好的活性，但耐受性更好，” 发言者表示，将这项工作定位为对更广泛 RAS 领域中新兴单药治疗进展的补充。</p>
<h2>超越 Ziihera 的合作伙伴带来的上行空间</h2>
<p>演讲者还指出了来自旧平台合作伙伴的价值。他们强调了 pasritamig，这是一种由强生公司开发的 KLK2 T 细胞激活剂，用于前列腺癌，表示早期临床数据已进入第三阶段研究，并可能成为强生未来前列腺癌业务的 “基石”。发言者表示，强生已指导该产品的峰值销售额为 10 亿至 50 亿美元，并指出 Zymeworks 拥有 “不错的里程碑和特许权使用费权益”。</p>
<h2>短期和中期里程碑</h2>
<p>展望未来，发言者列出了跨越 2025 年及以后的开发和监管里程碑。他们表示，zanidatamab 目前正在接受 FDA 审查，申请扩展标签至 HER2 阳性胃食管腺癌，并预计将为同一适应症提交额外的全球申请。他们还提到正在进行的乳腺癌研究，预计将在 2027 年底公布结果。</p>
<p>除了 zanidatamab 和强生在 pasritamig 方面的进展，报告者还描述了公司投资组合中即将发布的临床和前临床更新的更广泛节奏，并称 2026 年为 “丰富的催化剂” 之年。他们表示，Zymeworks 也在积极寻求建立更多的合作伙伴关系，并希望在这一年展示相关活动的成果。</p>
<p>最后，报告者表示，Zymeworks 旨在保持 “创新的研发公司”，同时引入一种以特许权使用费为导向的战略，以支持资金灵活性、潜在收购和股东回报，为公司在他们所描述的生物技术市场更具建设性的时期做好定位。</p>
<h2>关于 Zymeworks NASDAQ: ZYME</h2>
<p>Zymeworks Inc 是一家临床阶段的生物制药公司，致力于下一代多功能生物治疗药物的发现、开发和商业化。该公司专注于工程化抗体和蛋白质治疗，旨在解决肿瘤学和其他严重疾病中的一系列未满足的医疗需求。通过其专有平台，Zymeworks 旨在创造新型的双特异性和多特异性分子，这些分子可以同时与多个靶点结合，并招募免疫效应功能以增强效力和特异性。</p>
<p>Zymeworks 创新的核心是其 Azymetric™双特异性抗体平台，该平台能够设计具有可控组装和高稳定性的非对称双特异性抗体。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Zymeworks</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Zymeworks 吗？</h2>
<p>在你考虑 Zymeworks 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Zymeworks 并不在名单上。</p>
<p>虽然 Zymeworks 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ZYME

<p>Zymeworks（纳斯达克代码：ZYME）在 Bloom Burton 会议上进行了展示，强调其向首个获批产品 zanidatamab（Ziihera）的战略转变，以及来自特许权使用费的不断增长的收入来源。该公司旨在作为一个自给自足的实体运营，专注于资本配置而非筹款。Zymeworks 预计 zanidatamab 可能成为一个数十亿美元的畅销产品，得益于稳定的特许权使用费收入。该公司还保持着强大的抗体药物偶联物（ADCs）和多特异性抗体的研发管线，正在进行研究以提高癌症治疗的耐受性和疗效</p>

<ul>
<li>Zymeworks Offers Hope for More than Just Long-Term Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>Zymeworks 为不仅仅是长期投资者带来了希望</li>
</ul>
</div><p>Zymeworks NASDAQ: ZYME used a presentation at the Bloom Burton conference to outline how the company is repositioning itself around its first approved product and a growing stream of royalty and milestone revenue, while continuing to invest in internal research and development across antibody-drug conjugates (ADCs) and multispecific antibodies.</p>
<div class="lb-trans"><p>Zymeworks（纳斯达克代码：ZYME）在 Bloom Burton 会议上使用了一次演示，概述了公司如何围绕其首个获批产品和不断增长的特许权使用费及里程碑收入进行重新定位，同时继续在抗体药物偶联物（ADCs）和多特异性抗体方面投资内部研发。</p>
</div><p>The speaker, who noted it was the first time in five years they were presenting at an investor conference with Zymeworks’ stock “above where it was five years ago,” framed the update against what they described as improving sentiment in biotech, including increased M&amp;A activity and renewed investor credit for innovation in the sector.</p>
<div class="lb-trans"><p>发言者指出，这是他们五年来首次在投资者会议上展示 Zymeworks 的股票 “高于五年前的水平”，并将此次更新与他们所描述的生物技术领域情绪改善相结合，包括并购活动的增加和投资者对该领域创新的重新认可。</p>
</div><h2>Royalties shift the company’s financial strategy</h2>
<div class="lb-trans"><h2>特许权使用费改变公司的财务战略</h2>
</div><p>The presenter said Zymeworks now has “our first approved drug,” providing a revenue source that supports a new operating model. While the company does not have its own commercial organization, the speaker characterized partner-led sales revenue as “durable, long-term, and very substantial,” enabling Zymeworks to think about operating as a “self-funded entity” rather than relying on equity issuance to fund development.</p>
<div class="lb-trans"><p>演讲者表示，Zymeworks 现在拥有 “我们的首个获批药物”，提供了支持新运营模式的收入来源。尽管公司没有自己的商业组织，发言者将合作伙伴主导的销售收入描述为 “持久、长期且非常可观”，使 Zymeworks 能够考虑作为 “自筹资金实体” 运营，而不是依赖股权发行来资助开发。</p>
</div><p>They added that the company recently completed a financing with Royalty Pharma, describing it as borrowing against future cash flows in order to invest in “R&amp;D, acquisitions, and returning capital back to shareholders.” The presenter said the company was “well-funded,” citing $271 million (and noting that figure does not include $250 million in royalty proceeds), and argued that the discussion has shifted from cash runway to capital allocation.</p>
<div class="lb-trans"><p>他们补充说，公司最近与 Royalty Pharma 完成了一项融资，将其描述为借用未来现金流以投资于 “研发、收购和向股东返还资本”。演讲者表示，公司 “资金充足”，引用了 2.71 亿美元（并指出该数字不包括 2.5 亿美元的特许权使用费收入），并认为讨论已从现金周转转向资本配置。</p>
</div><p>“We don’t have a capital problem, we have a capital allocation problem,” the speaker said, describing a goal to build shareholder value by balancing internal innovation with disciplined spending and new ways to deploy cash flow.</p>
<div class="lb-trans"><p>“我们没有资本问题，我们有资本配置问题，” 发言者表示，描述了通过平衡内部创新与有纪律的支出以及新的现金流部署方式来建立股东价值的目标。</p>
</div><h2>Zanidatamab as the foundation for a new model</h2>
<div class="lb-trans"><h2>Zanidatamab 作为新模型的基础</h2>
</div><p>The strategic pivot is centered on zanidatamab, marketed as Ziihera, which the presenter said was invented at Zymeworks and advanced into Phase 3 before being partnered with Jazz Pharmaceuticals and BeOne (formerly BeiGene). The speaker emphasized that the partnership structure preserved what they called a “really considerable share” of future royalties and milestones.</p>
<div class="lb-trans"><p>战略转变以 zanidatamab 为中心，市场名称为 Ziihera，演讲者表示该药物是在 Zymeworks 发明并推进至第三阶段，然后与 Jazz Pharmaceuticals 和 BeOne（前身为 BeiGene）合作。发言者强调，合作伙伴结构保留了他们所称的未来特许权使用费和里程碑的 “相当可观份额”。</p>
</div><p>Looking back, the presenter said Zymeworks viewed zanidatamab in 2022 as a potential “billion-dollar compound,” but argued expectations have risen. They said it is “above consensus beyond that now,” and added, “We think zanidatamab’s going to be a multi-billion-dollar seller.” They attributed that view to clinical data and potential applicability in additional settings, and they emphasized what they see as differentiation in the HER2 landscape, stating that “Zani’s the only one” among HER2 bispecific antibodies currently on the market or in development.</p>
<div class="lb-trans"><p>回顾过去，演讲者表示 Zymeworks 在 2022 年将 zanidatamab 视为潜在的 “十亿美元化合物”，但认为预期已经上升。他们表示，现在 “超出共识”，并补充道：“我们认为 zanidatamab 将成为一个数十亿美元的畅销药。” 他们将这一观点归因于临床数据和在其他适应症中的潜在适用性，并强调他们所看到的 HER2 领域的差异化，表示 “Zani 是唯一一个” 在市场上或正在开发的 HER2 双特异性抗体。</p>
</div><p>The speaker also said the expected durability of the royalty stream supports a long planning horizon, describing cash flows as lasting “at least out to 2039, if not further.” With that base, they said Zymeworks aims to operate as a “positive revenue company” with “growing revenue over a long-term,” translating that into profitability while still investing in R&amp;D.</p>
<div class="lb-trans"><p>发言者还表示，预期的特许权使用费流的持久性支持了长期规划，描述现金流将持续 “至少到 2039 年，甚至更久。” 在此基础上，他们表示 Zymeworks 的目标是作为一家 “正收入公司” 运营，保持 “长期增长的收入”，并将其转化为盈利，同时仍然投资于研发。</p>
</div><h2>Pipeline focus and AACR updates</h2>
<div class="lb-trans"><h2>管道重点和 AACR 更新</h2>
</div><p>On the R&amp;D side, the presenter said Zymeworks maintains a “very full pipeline” of ADCs and multi-specific antibodies. They noted that, beyond zanidatamab, the company’s pipeline assets are “unpartnered,” which they said provides “a lot of optionality” for future partnerships while keeping potential upside unencumbered.</p>
<div class="lb-trans"><p>在研发方面，演讲者表示 Zymeworks 保持着 “非常充实的管道”，包括 ADCs 和多特异性抗体。他们指出，除了 zanidatamab 外，公司管道资产是 “未合作的”，这为未来的合作提供了 “很多选择”，同时保持潜在的上行空间不受限制。</p>
</div><p>At the American Association for Cancer Research (AACR) meeting, the speaker said Zymeworks had seven presentations focused largely on its ADC platform. They highlighted an oral presentation scheduled for the same day on ZW191, an ADC targeted in ovarian cancer tumors, and said a press release would accompany the data.</p>
<div class="lb-trans"><p>在美国癌症研究协会（AACR）会议上，发言者表示 Zymeworks 有七个演示，主要集中在其 ADC 平台上。他们强调了当天安排的 ZW191 的口头报告，该 ADC 针对卵巢癌肿瘤，并表示将会有新闻稿伴随数据发布。</p>
</div><p>They also spent time discussing what they described as next-generation ADC concepts, including payloads designed to deliver pan-RAS inhibitors. The presenter said the company had explored multiple payload directions—such as different toxins, bispecifics, and protein degraders—before choosing to test whether small-molecule inhibitors could be more effective when delivered via an ADC construct.</p>
<div class="lb-trans"><p>他们还花时间讨论了他们所描述的下一代 ADC 概念，包括旨在传递全 RAS 抑制剂的载荷。演讲者表示，公司探索了多种载荷方向——例如不同的毒素、双特异性抗体和蛋白降解剂——然后选择测试小分子抑制剂在通过 ADC 构建传递时是否更有效。</p>
</div><p>They characterized the approach as early-stage but said the goal is to pursue activity with improved tolerability that could enable combination regimens. “We think an ADC construct could deliver same or better activity, but with better tolerability,” the speaker said, positioning the work as complementary to emerging monotherapy advances in the broader RAS landscape.</p>
<div class="lb-trans"><p>他们将这种方法描述为早期阶段，但表示目标是追求具有改善耐受性的活性，以便能够实现联合方案。“我们认为 ADC 构建可以提供相同或更好的活性，但耐受性更好，” 发言者表示，将这项工作定位为对更广泛 RAS 领域中新兴单药治疗进展的补充。</p>
</div><h2>Partnership-derived upside beyond Ziihera</h2>
<div class="lb-trans"><h2>超越 Ziihera 的合作伙伴带来的上行空间</h2>
</div><p>The presenter also pointed to value from older platform partnerships. They highlighted pasritamig, a KLK2 T-cell engager being developed by Johnson &amp; Johnson for prostate cancer, saying early clinical data has progressed into Phase 3 studies and could become a “cornerstone” of J&amp;J’s future prostate cancer franchise. The speaker said J&amp;J has guided to $1 billion to $5 billion in peak sales for the product and noted Zymeworks has “a nice milestone and royalty interest.”</p>
<div class="lb-trans"><p>演讲者还指出了来自旧平台合作伙伴的价值。他们强调了 pasritamig，这是一种由强生公司开发的 KLK2 T 细胞激活剂，用于前列腺癌，表示早期临床数据已进入第三阶段研究，并可能成为强生未来前列腺癌业务的 “基石”。发言者表示，强生已指导该产品的峰值销售额为 10 亿至 50 亿美元，并指出 Zymeworks 拥有 “不错的里程碑和特许权使用费权益”。</p>
</div><h2>Near- and mid-term milestones</h2>
<div class="lb-trans"><h2>短期和中期里程碑</h2>
</div><p>Looking ahead, the speaker listed development and regulatory milestones spanning 2025 and beyond. They said zanidatamab is currently under FDA review for a label expansion into HER2-positive gastroesophageal adenocarcinoma, and they expect additional global filings for the same indication. They also noted an ongoing breast cancer study, which they said is expected to read out in late 2027.</p>
<div class="lb-trans"><p>展望未来，发言者列出了跨越 2025 年及以后的开发和监管里程碑。他们表示，zanidatamab 目前正在接受 FDA 审查，申请扩展标签至 HER2 阳性胃食管腺癌，并预计将为同一适应症提交额外的全球申请。他们还提到正在进行的乳腺癌研究，预计将在 2027 年底公布结果。</p>
</div><p>In addition to zanidatamab and J&amp;J’s progress on pasritamig, the presenter described a broader cadence of upcoming clinical and preclinical updates across the company’s portfolio, calling 2026 a “rich catalyst” year. They said Zymeworks is also actively working to build additional partnerships and collaborations and hopes to show results from that activity during the year.</p>
<div class="lb-trans"><p>除了 zanidatamab 和强生在 pasritamig 方面的进展，报告者还描述了公司投资组合中即将发布的临床和前临床更新的更广泛节奏，并称 2026 年为 “丰富的催化剂” 之年。他们表示，Zymeworks 也在积极寻求建立更多的合作伙伴关系，并希望在这一年展示相关活动的成果。</p>
</div><p>Concluding, the presenter said Zymeworks is aiming to remain an “innovative R&amp;D company” while layering in a royalty-oriented strategy that supports funding flexibility, potential acquisitions, and shareholder returns, positioning the company for what they described as a more constructive period for biotechnology markets.</p>
<div class="lb-trans"><p>最后，报告者表示，Zymeworks 旨在保持 “创新的研发公司”，同时引入一种以特许权使用费为导向的战略，以支持资金灵活性、潜在收购和股东回报，为公司在他们所描述的生物技术市场更具建设性的时期做好定位。</p>
</div><h2>About Zymeworks NASDAQ: ZYME</h2>
<div class="lb-trans"><h2>关于 Zymeworks NASDAQ: ZYME</h2>
</div><p>Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.</p>
<div class="lb-trans"><p>Zymeworks Inc 是一家临床阶段的生物制药公司，致力于下一代多功能生物治疗药物的发现、开发和商业化。该公司专注于工程化抗体和蛋白质治疗，旨在解决肿瘤学和其他严重疾病中的一系列未满足的医疗需求。通过其专有平台，Zymeworks 旨在创造新型的双特异性和多特异性分子，这些分子可以同时与多个靶点结合，并招募免疫效应功能以增强效力和特异性。</p>
</div><p>At the core of Zymeworks' innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.</p>
<div class="lb-trans"><p>Zymeworks 创新的核心是其 Azymetric™双特异性抗体平台，该平台能够设计具有可控组装和高稳定性的非对称双特异性抗体。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Zymeworks</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Zymeworks</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Zymeworks Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Zymeworks 吗？</h2>
</div><p>Before you consider Zymeworks, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Zymeworks 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Zymeworks 并不在名单上。</p>
</div><p>While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zymeworks 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera

Market Beat

Zymeworks 在 Bloom Burton 会议上强调了其以版税为驱动的战略转型，并将目标锁定在数十亿美元的 Ziihera